Synexo Group (SYNEXO) Q1 2026 earnings summary
Event summary combining transcript, slides, and related documents.
Q1 2026 earnings summary
15 May, 2026Executive summary
Achieved 76% year-over-year ARR growth on a pro forma, organic basis, with live ARR reaching SEK 6.03m and strong upsell and market share gains.
Backlog increased by 70%, with signed ARR at SEK 10.2m, providing strong forward revenue visibility and a significant portion expected to go live in the next twelve months.
Gross margin improved to 66% in Q1 2026, up from 57% in Q4 2025, reflecting operational scaling and efficiency gains, with a target of >70% by 2026.
Norwegian subsidiaries delivered positive EBITDA (SEK 46k), but total Group EBITDA was negative (SEK -597k) due to parent costs and non-recurring relisting expenses.
The Group remains debt-free with SEK 1.4m in cash and an equity ratio of approximately 92% at period end.
Financial highlights
Q1'26 ARR grew 20% quarter-over-quarter (109% annualized), driven by 76% new logos and 33% net upsell, partially offset by 9% churn.
Pro forma revenue increased to SEK 1.3m in Q1 2026 from SEK 0.8m in Q1 2025, a 50% year-over-year increase.
Gross profit rose to SEK 846k, with gross margin up to 66% from 62% year-over-year.
Cash-EBITDA remained negative in Q1'26 but is expected to turn positive in Q2'26 as backlog converts.
No interest-bearing debt and SEK 1.4m cash position at quarter-end.
Outlook and guidance
Targeting live ARR of SEK 12m (>100% organic growth) in 2026, with 48% already secured through signed contracts.
Total signed ARR targeted to exceed SEK 18m by year-end 2026.
Gross margin expected to surpass 70%, with no planned increase in overhead costs.
Cash-EBITDA projected to be positive from Q2'26 onward; management expects Group-level profitability by end of Q2 2026 as overheads are scaled.
Medium-term guidance: >20% average organic annual growth and continued margin expansion.
Latest events from Synexo Group
- High-growth, profitable BaaS platform with strong retention and disciplined M&A strategy.SYNEXO
Investor presentation15 May 2026 - ARR up 61% y/y, strong upsell, low churn, and M&A activity drive growth and margin targets.SYNEXO
Q4 202526 Feb 2026 - Strong organic growth, high margins, and disciplined M&A drive scalable, shareholder-focused value.SYNEXO
Investor Presentation2 Jan 2026 - Q3 2025 delivered 56% pro forma revenue growth, 63% gross margin, and strong ARR expansion.SYNEXO
Q3 202528 Nov 2025 - No operations remain after subsidiary sale; future depends on a pending data storage acquisition.SYNEXO
Q2 202521 Aug 2025 - Sales dropped sharply and losses deepened, with recovery delayed to 2025/2026.SYNEXO
Q3 202413 Jun 2025 - Net sales dropped 43.6% and a SEK 2.6 million order was secured from Pathogen Systems Inc.SYNEXO
Q2 202413 Jun 2025 - Sales up, losses persist; MedTech order and new partnerships drive future focus.SYNEXO
Q1 20256 Jun 2025 - Omsättning föll 39% och fortsatt förlust kräver ny finansiering och omstrukturering.SYNEXO
Q4 20245 Jun 2025